MX2018011837A - Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas. - Google Patents

Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas.

Info

Publication number
MX2018011837A
MX2018011837A MX2018011837A MX2018011837A MX2018011837A MX 2018011837 A MX2018011837 A MX 2018011837A MX 2018011837 A MX2018011837 A MX 2018011837A MX 2018011837 A MX2018011837 A MX 2018011837A MX 2018011837 A MX2018011837 A MX 2018011837A
Authority
MX
Mexico
Prior art keywords
compositions
alphaviruses
methods
stabilizing
live
Prior art date
Application number
MX2018011837A
Other languages
English (en)
Spanish (es)
Inventor
Ann Livengood Jill
Duane Powell Timothy
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2018011837A publication Critical patent/MX2018011837A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2018011837A 2016-03-31 2017-03-27 Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas. MX2018011837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316262P 2016-03-31 2016-03-31
PCT/US2017/024365 WO2017172643A1 (en) 2016-03-31 2017-03-27 Compositions and methods for stabilizing alphaviruses with improved formulations

Publications (1)

Publication Number Publication Date
MX2018011837A true MX2018011837A (es) 2019-02-13

Family

ID=58537071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011837A MX2018011837A (es) 2016-03-31 2017-03-27 Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas.

Country Status (19)

Country Link
US (2) US10632184B2 (cg-RX-API-DMAC7.html)
EP (1) EP3436063A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019513138A (cg-RX-API-DMAC7.html)
KR (1) KR20180135912A (cg-RX-API-DMAC7.html)
CN (1) CN109069614A (cg-RX-API-DMAC7.html)
AU (1) AU2017241590A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018069035A2 (cg-RX-API-DMAC7.html)
CA (1) CA3019529A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018010357A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180456A (cg-RX-API-DMAC7.html)
DO (1) DOP2018000211A (cg-RX-API-DMAC7.html)
EC (1) ECSP18081486A (cg-RX-API-DMAC7.html)
MX (1) MX2018011837A (cg-RX-API-DMAC7.html)
NI (1) NI201800096A (cg-RX-API-DMAC7.html)
PE (1) PE20190149A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018502119A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201808458QA (cg-RX-API-DMAC7.html)
SV (1) SV2018005747A (cg-RX-API-DMAC7.html)
WO (1) WO2017172643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087188A1 (en) 2013-12-23 2016-11-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
AU2020327602A1 (en) * 2019-08-09 2022-01-27 Valneva Se Chikungunya vaccine formulations
PH12021553187A1 (en) * 2019-08-09 2022-11-07 Valneva Se Single shot chikungunya virus vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545555A (en) 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
WO2008026225A2 (en) * 2006-09-01 2008-03-06 Bharat Biotech International Limited A vaccine for chikungunya virus infection
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
CN111729077A (zh) * 2013-03-14 2020-10-02 武田疫苗股份有限公司 减毒活甲病毒制剂的组合物和方法
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗

Also Published As

Publication number Publication date
PH12018502119A1 (en) 2019-07-15
DOP2018000211A (es) 2018-12-31
US20190111124A1 (en) 2019-04-18
KR20180135912A (ko) 2018-12-21
CO2018010357A2 (es) 2019-05-21
JP2019513138A (ja) 2019-05-23
NI201800096A (es) 2019-02-01
ECSP18081486A (es) 2019-01-31
CN109069614A (zh) 2018-12-21
SV2018005747A (es) 2019-03-28
US20200306361A1 (en) 2020-10-01
SG11201808458QA (en) 2018-10-30
PE20190149A1 (es) 2019-01-22
WO2017172643A1 (en) 2017-10-05
EP3436063A1 (en) 2019-02-06
US10632184B2 (en) 2020-04-28
CA3019529A1 (en) 2017-10-05
AU2017241590A1 (en) 2018-10-11
CR20180456A (es) 2019-01-09
BR112018069035A2 (pt) 2019-01-29

Similar Documents

Publication Publication Date Title
ZA201802331B (en) Stable inoculant compositions and methods for producing same
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
PH12016502479A1 (en) Formulated receptor polypeptides and related methods
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2019004611A (es) Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas.
MX2017009720A (es) Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas.
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
MX369223B (es) Composiciones de protector solar.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
PH12017500836A1 (en) Transdermal formulations
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
GB2568181A (en) Wheat
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
PH12018502119A1 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
MX2019013642A (es) Compuestos, composiciones y metodos.
PH12015502115A1 (en) Compositions and methods for live, attenuated alphavirus formulations
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
CA3056612A1 (en) Analogs of deutetrabenazine, their preparation and use
UA88646U (uk) Перфторароматичні ізомерні дифторфенілазометинфенілові етери як мономери для поліетеразометинів
MX2016001694A (es) Formulacion de vacuna de sacarido.